News and Events

Latest News

Stay up to date on all Relief activities.

Our team is working diligently to rapidly develop RLF-100™ for the benefit of COVID-19 patients. Here you will find latest news, upcoming events and interviews.

Corporate News

Archive

Relief, NeuroRx and Quantum Leap announce the inclusion of ZYESAMI™ (RLF-100™: aviptadil) in the I-SPY COVID-19 Trial

11 January 2021
Relief and NeuroRx Conclude Enrollment in their Phase 2b/3 Trial of RLF-100™ for Critical COVID-19 with Respiratory Failure

30 December 2020
Relief Appoints Chris L.J.J. Stijnen as Chief Commercial Officer

21 December 2020
Relief Announces Results of Extraordinary General Meeting of RELIEF THERAPEUTICS Holding AG Approved with Large Majority

18 December 2020
Relief Therapeutics and NeuroRx Meet 165 Patient Enrollment Target in Phase 2b/3 Trial of RLF-100™ for Critical COVID-19 with Respiratory Failure

07 December 2020
Correction: NeuroRx and Relief announce initial successful results from expanded access use of RLF-100™ (aviptadil) in patients with Critical COVID-19 and Severe Comorbidity: 72% survival seen in ICU patients

25 November 2020
NeuroRx and Relief announce initial successful results from expanded access use of RLF-100™ (aviptadil) in patients with Critical COVID-19 and Severe Comorbidity: 72% survival seen in ICU patients

24 November 2020
Relief Announces Notice of Extraordinary General Meeting of RELIEF THERAPEUTICS Holding AG

23 November 2020
Relief Selects CRO and CDMO for RLF-100TM in Europe

18 November 2020
Relief, with Partner NeuroRx, Announces Enrollment of 150 Patients in Phase 2b/3 Trial of RLF-100™ for Critical COVID-19 with Respiratory Failure

13 November 2020

Scientific Publications

Media Contact

For media inquires contact:

MC Services AG
Anne Hennecke / Brittney Sojeva
Mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
Tel.: +49 (0) 211-529-252-14

Company

Pipeline

Investor Relations

News and Events

Privacy Policy

Disclaimer

Imprint

© relief therapeutics 2020